# Pluri Inc. (PLUR) · Edgar & Edgarette company card

> Pluri (PLUR) saw revenue fall 24.0% in FY2026 to $1 million, operating margin -2455% against a -15.8% median for biological products, (no diagnostic substances), equity -92.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1158780 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/PLUR) · [JSON](https://www.pops4.com/boards/company/PLUR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | -24.0% |
| Revenue growth per year | 44.4% |
| Operating margin | -2454.5% (prior year -1659.9%) |
| Net margin | -2496.9% |
| Operating cash flow | −$20M |
| Capital spending | $633,000 |
| Free cash flow | −$20M |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $25M |
| Total equity | −$23M |
| Equity ÷ assets | -92.6% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -74.75 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -2454.5% in FY2026; revenue is hard to predict: its 80% range is ±50%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $1.0M (FY2026). Experience: revenue down 24.0% on the year, up 44.4% a year over 4 years; operating margin -2454.5%, down from -1659.9%. Soundness: equity -92.6% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $654K and $2.0M next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $607K to $2.1M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -2454.5% against a -15.8% median; growth -24.0% against 21.4%.

Range logged 2026-09-24, receipt 51e2f80e5f76e89f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-07-13 ([filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026077548/0001213900-26-077548-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-22 ([filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026070609/0001213900-26-070609-index.htm))

## Recent filings

- 8-K · filed 2026-10-30 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026114079/0001213900-26-114079-index.htm)
- 8-K · filed 2026-10-20 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026111015/0001213900-26-111015-index.htm)
- S-1 · filed 2026-10-06 · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026107182/0001213900-26-107182-index.htm)
- 10-K · filed 2026-09-10 · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/0001213900-26-098862-index.htm)
- 8-K · filed 2026-08-28 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026094638/0001213900-26-094638-index.htm)
- 8-K · filed 2026-08-17 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1158780/000121390026090738/0001213900-26-090738-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001158780.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1158780

## Cite

POPS4, Edgar & Edgarette: Pluri Inc. (PLUR) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PLUR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.